- New board consists of diversified experts with domestic and
international business, academia, agriculture, trade and healthcare
expertise
- Half of new board members are businesswomen, reflecting the
overall balance of Company's workforce and commitment to
inclusivity
- Board's mandate is focused on the Company's domestic growth and
regulatory relations, aligned to support the international
operations of parent company PharmaCielo Ltd.
RIONEGRO, Colombia,
Aug. 2, 2019 /CNW/ - The executive
management team of PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF) is
pleased to announce the appointment of a new Board of
Directors for its wholly owned subsidiary, PharmaCielo
Colombia Holdings S.A.S., ("PharmaCielo Colombia" or the "Company")
the premier cultivator and producer of medicinal-grade cannabis
oils and extracts in Colombia. The
new Board consists of a diversified group of experts with domestic
and international business, trade, agriculture and healthcare
expertise. The Board's mandate is focused on PharmaCielo Colombia
operations, domestic growth and regulatory relationships in support
of the continued international expansion of the parent company. The
appointment of the new Board members is subject to TSX Venture
Exchange approval.
"I am thrilled to start working alongside this great and
eclectic group of experts to help navigate PharmaCielo Colombia's
operations and growth in this evolving and ever-changing regulatory
sector," said Carlos Manuel Uribe,
Chair of the Board. "The Board also acknowledges the role
PharmaCielo Colombia plays in enabling the international expansion
of the parent company. As such, we are fully aligned with the
global management team and will work in synergy toward our common
business objective – becoming the global leader and provider of
medicinal cannabis oils and derived products."
Of special note is that nearly half of the newly appointed Board
members of PharmaCielo Colombia are businesswomen, further
cementing the Company's longstanding and ongoing commitment to
promote diversity and inclusivity within its ranks.
"The original Board of Directors made a significant contribution
to the establishment of the subsidiary company in its early days,
for which they must be recognized and thanked," said David Attard, PharmaCielo Ltd. CEO. "We
appreciate their contributions as well as the fact that those
individuals remain strongly supportive of the company, even as the
business continues to develop and grow, with ever-evolving needs
for support."
Members of the PharmaCielo Colombia Board of
Directors
The new Board members are:
- Claudia Jiménez, has a Doctorate in Law and is a Manager
and Partner with business consultancy firm Jiménez & Asociados.
Ms. Jiménez brings a wealth of international business and
diplomatic experience to PharmaCielo Colombia as a former Executive
Director of the Association of the Large-Scale Mining Sector,
former Minister Counselor with the Government of Colombia and an Ambassador in Switzerland and Liechtenstein, among other roles.
- Maria Fernanda
Saldarriaga is a Business Development & Operations
Lead at Radical Venture LLC with academic background in marketing
and supply-chain management. Previously she was the General Manager
and New Business Development Lead at the Fastrack Institute and
acted as mentor with Quantica, a not-for-profit organization that
provides a platform and training for social entrepreneurship.
- Silvia Ochoa is the head
of Corporate Social Responsibility (CSR) for COMFAMA, an
organization that is responsible for providing support and services
to the department of Antioquia. Previously, Ms. Ochoa served as
Vice President with TIGO UNE B2B, a telecommunications firm. Ms.
Ochoa holds a degree in electronic engineering from Universidad
Pontificia Bolivariana.
- Jorge Julián Osorio is the Dean of CES University's
School of Medicine in Medellín, where he obtained his medical
degree. Mr. Osorio is also the president of ASCOFAME, the Colombian
Association of Faculties of Medicine, and is a member of several
hospital boards.
The following Board members will continue as members of the
Board:
- Andrés Fernández Acosta is a former Minister of
Agriculture who held various senior positions in the sector
following his tenure in the cabinet, including Director of the
Colombian Institute of Agriculture (ICA). Currently, Mr. Acosta
serves as an administrator of agricultural companies and manager of
a real estate fund and of Fundarias, a landscape investment
management company.
- Carlos Manuel Uribe is
the General Manager of Flores El Capiro
S.A., the world's largest exporter of flowers by sea freight
and one of the top three largest growers of chrysanthemums in the
world. Mr. Uribe is presently chairman of the board of
ASOCOLFLORES. He serves on the boards of several companies
including Ruta N, a public joint venture created to inspire and
encourage innovation in Medellín; COMFAMA, an organization that
offers services to the population of Antioquia in multiple areas of
health and well-being; Cartama S.A., the largest avocado producer
in Colombia; Pegaucho S.A.S., a
Colombian adhesives/sealants producer; and Savannah Crops S.A.S.,
the largest MD2 pineapple producer in Colombia.
- Federico Cock-Correa is
one of PharmaCielo's co-founders and a master horticulturist with
30 years of management experience, utilizing innovative technology
to develop new crops and enhance horticultural production
techniques. He has served as general manager, board member, partner
and founder of numerous horticultural businesses in Rionegro,
Antioquia. Mr. Cock-Correa is a member of the national board of
directors of Colombian Flower Exporters Association (ASOCOLFLORES)
and has been a member or officer of Business Corporation for
Eastern Antioquia (CEO), Colombian Floriculture Innovation Center
(CENIFLORES) and the Floral Products Trade Association (WFFSA). He
currently represents PharmaCielo on the board of the Asociación
Colombiana de Industrias del Cannabis (ASOCOLCANNA).
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF) is a global company,
headquartered in Canada, with a
focus on ethically and sustainably processing and supplying all
natural, medicinal-grade cannabis oil extracts and related products
to large channel distributors. PharmaCielo's principal (and wholly
owned) subsidiary is PharmaCielo Colombia Holdings S.A.S.,
headquartered at its nursery and propagation centre located in
Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by the use of words
such as, "expects", "is expected", "intends", "believes", or
variations of such words and phrases or state that certain actions,
events or results "may" or "will" be taken, occur or be achieved.
Forward-looking statements include statements with respect to the
approval of the new Board members by the TSXV and the international
expansion of the operations of PharmaCielo Ltd. Forward-looking
statements are based on assumptions, including with respect to
PharmaCielo's planned products, and the ability to execute its
business plan that management believes are reasonable in the
circumstances, but the actual results, performance or achievements
of PharmaCielo's business may be materially different from any
future results, performance or achievements expressed or implied by
any forward-looking statements. Forward-looking statements can be
affected by known and unknown risks, uncertainties and other
factors, including, but not limited to, the equity markets
generally, risks associated with early stage companies, risks
associated with the regulation of cannabis and cannabinoid
derivatives, failure to obtain necessary TSXV approval, competition
for PharmaCielo's planned products, risks associated with operating
in Colombia, and currency exchange
risk. Accordingly, readers should not place undue reliance on
forward-looking statements.
Except as required by law, PharmaCielo undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE PharmaCielo Ltd.